Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Kasper, S; Quiner, S; Barnas, C; Fabisch, H; Haushofer, M; Sackel, C; König, P; Lingg, A; Platz, T; Rittmannsberger, H; Stuppäck, C; Willeit, M; Zapotoczky, HG.
Zotepine in the treatment of acute hospitalized schizophrenic episodes.
INT CLIN PSYCHOPHARMACOL. 2001; 16(3): 163-168. Doi: 10.1097%2F00004850-200105000-00005
Web of Science FullText FullText_MUG

Co-authors Med Uni Graz: Fabisch Johann
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: The atypical antipsychotic zotepine was studied in an open, multicentre uncontrolled, post-marketing surveillance study in 108 schizophrenic patients hospitalized in 12 trial centres in Austria. Within the dosage range of 50-450 mg (mean at the end of the study, 207 +/- 125 mg/day), a significant reduction of positive as well as negative symptoms was noted. There was no increase in extrapyramidal side-effects during the study and a significant decrease in akathisia scores. The medication was well tolerated during the 42-day observation period. Zotepine improved both positive and negative symptoms and was not accompanied by extrapyramidal side-effects, justifying its classification as an atypical antipsychotic. Int clin Psychopharmacol 16:163-168 (C) 2001 Lippincott Williams & Wilkins.
Find related publications in this database (Keywords): antipsychotics; atypical antipsychotics; post-marketing surveillance study; schizophrenia; zotepine